Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Immunophenotypic characteristics of brain metastases

https://doi.org/10.14412/2074-2711-2018-4-59-64

Full Text:

Abstract

Up to 15% of patients with secondary brain tumors of unknown primary are admitted to a neurosurgery department. Identification of a primary tumor site on the basis of surgical material immunophenotyping in routine clinical practice has a significant potential; however, this requires systematization.

Objective: to detect the primary focus of brain carcinoma. Patients and methods.Surgical specimens from 7 patients with brain tumor of unknown primary were investigated using light optical microscopy and an immunohistochemical (IHC) panel including EMA, CK AE1/3, CK7, CK5/6, GFAP, S-100, Vimentin, p63, TTF-1, Uroplakin III (UPIII), CDX2, and Her2/neu.

Results and discussion. A study using the IHC panel made it possible to obtain the following tumor phenotypes in the patients: CK5/6+, p63+, CK7+, UPIII+ (urothelial cancer) (n=3); CK5/6-, CK7+, TTF-1+, CDX2- (lung adenocarcinoma) (n=2); CK5/6+, p63+, CK7-, UPIII, TTF-1- (squamous cell carcinoma) (n=1), and  CK5/6-, CK7+, TTF-1-, CDX2-, Her2/neu+ (breast cancer) (n=1). Evidence of the primary focus of the tumors was subsequently confirmed by instrumental techniques in all cases when cancer of the breast, lung and urinary system was directly sought. The findings were used to elaborate an algorithm for the differential diagnostic immunophenotyping of brain metastases.

Conclusion. The primary focus of brain carcinoma was detected in all cases on the proposed IHC panel. The systematized algorithm for differential diagnostic immunophenotyping can be used in clinical practice.

About the Authors

G. A. Demyashkin
Medical Diagnostic Center Nine, Ministry of Defense of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Aleksandrovich Demashkin

13a, Komsomolsky Prospect, Moscow 119146; 8, Trubetskaya St., Build. 2, Moscow 119991



E. A. Shalamova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

8, Trubetskaya St., Build. 2, Moscow 119991



P. V. Nikitin
Acad. N.N. Burdenko National Research and Practical Center for Neurosurgery, Ministry of Health of Russia
Russian Federation

16, Fourth Tverskaya-Yamskaya St., Moscow 125047



S. N. Bogomolov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

8, Trubetskaya St., Build. 2, Moscow 119991



References

1. Davis FG, Dolecek TA, McCarthy BJ, et al. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol. 2012 Sep;14(9):1171-7. doi: 10.1093/neuonc/nos152. Epub 2012 Aug 16.

2. Gavrilovic I, Posner J. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005 Oct;75(1):5-14. doi:10.1007/s11060-0048093-6.

3. Fox B, Cheung V, Patel A, et al. Epidemiology of Metastatic Brain Tumors. Neurosurg Clin N Am. 2011 Jan;22(1):1-6, v. doi: 10.1016/j.nec.2010.08.007.

4. Sharma P, Trivedi P, Shah MJ. Evaluation of central nervous system metastases with immunohistochemistry correlation. Indian J Pathol Microbiol 2014;57:376-9.

5. Fink KR, Fink JR. Imaging of brain metastases. Surg Neurol Int. 2013 May 2;4(Suppl 4): S209-19. doi: 10.4103/2152-7806.111298.Print 2013.

6. Jaiswal S. Role of immunohistochemistry in the diagnosis of central nervous system tumors. Neurol India. 2016 May-Jun;64(3):502-12. doi: 10.4103/0028-3886.181547.

7. Lin F, Liu H. Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin. Arch Pathol Lab Med. 2014 Dec;138(12): 1583-610. doi: 10.5858/arpa.2014-0061-RA.

8. Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody. Diagn Pathol. 2012 Jan 23;7:9. doi: 10.1186/1746-1596-7-9.

9. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: a review and update. Appl Immunohistochem Mol Morphol. 2012 Oct;20(5):429-44. doi:10.1097/PAI.0b013e31825439bc.

10. Sinna EA, Ezzat N, Sherif GM. Role of thyroid transcription factor-1 and P63 immunocytochemistry in cytologic typing of non-small cell lung carcinomas. J Egypt Natl Canc Inst. 2013 Dec;25(4):209-18. doi: 10.1016/j.jnci.2013.05.005

11. Hayashi T, Sentani K, Kakumoto S, et al. Prognostic impact of immunohistochemical classification of bladder cancer according to luminal (Uroplakin III) and basal (Cytokeratin 5/6) markers. Eur Urol Suppl. 2017;16(3):e681.

12. Arslan UY, Oksuzoglu B, Aksoy S, et al. Breast cancer subtypes and outcomes of central nervous system metastases. Breast. 2011 Dec; 20(6):562-7. doi: 10.1016/j.breast.2011.07.017

13. Montemurro F, Sarotto I, Casorzo L, et al. HER2 and central nervous system metastasis in patients with breast cancer. Clin Breast Cancer. 2004 Aug;5(3):232-4.

14. Kashima K, Hashimoto H, Nishida H, et al. Significant Expression of Thyroid Transcription Factor-1 in Pulmonary Squamous Cell Carcinoma Detected by SPT24 Monoclonal Antibody and CSA-II System. Applied Immunohistochemistry & Molecular Morphology. 2014;22(2):119-24. doi:10.1097/pai.0b013e31828acad2.


For citation:


Demyashkin G.A., Shalamova E.A., Nikitin P.V., Bogomolov S.N. Immunophenotypic characteristics of brain metastases. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):59-64. (In Russ.) https://doi.org/10.14412/2074-2711-2018-4-59-64

Views: 196


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)